Opinion

Video

Overview of Efficacy and Safety Data for Current CLL Treatment Options

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Image of man with brown hair.
Image of a man wearing a black button-up shirt.
Related Content
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL)!
January 10th 2025

Learning to ‘Let it Be’ After Poor Test Results

Chester Freeman
When I recognize my frustration and dissapointment with the test results for my chronic lymphocytic leukemia, I find comfort in listening to music.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Image of woman writing with pen.
December 30th 2024

Top Contributor Stories from 2024

Alex Biese
Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
Illustration of red blood cells.
December 23rd 2024

Epkinly Leads to Responses in Heavily Pretreated Patients With CLL

Gina Mauro
Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.
Image of red blood cells.
December 18th 2024

Imbruvica-Venetoclax Shows Promise in Managing CLL

Spencer Feldman
A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.